| 000 | 01805 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250515130318.0 | ||
| 264 | 0 | _c20081023 | |
| 008 | 200810s 0 0 eng d | ||
| 022 | _a1879-1891 | ||
| 024 | 7 |
_a10.1016/j.ajo.2008.05.036 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKrohne, Tim U | |
| 245 | 0 | 0 |
_aIntraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. _h[electronic resource] |
| 260 |
_bAmerican journal of ophthalmology _cOct 2008 |
||
| 300 |
_a508-12 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xpharmacokinetics |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xpharmacokinetics |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAqueous Humor _xmetabolism |
| 650 | 0 | 4 | _aBevacizumab |
| 650 | 0 | 4 |
_aCataract _xcomplications |
| 650 | 0 | 4 | _aCataract Extraction |
| 650 | 0 | 4 |
_aDiabetic Retinopathy _xcomplications |
| 650 | 0 | 4 | _aEnzyme-Linked Immunosorbent Assay |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections |
| 650 | 0 | 4 |
_aMacular Degeneration _xcomplications |
| 650 | 0 | 4 |
_aMacular Edema _xetiology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aRetinal Vein Occlusion _xcomplications |
| 650 | 0 | 4 |
_aVascular Endothelial Growth Factor A _xantagonists & inhibitors |
| 650 | 0 | 4 | _aVitreous Body |
| 700 | 1 | _aEter, Nicole | |
| 700 | 1 | _aHolz, Frank G | |
| 700 | 1 | _aMeyer, Carsten H | |
| 773 | 0 |
_tAmerican journal of ophthalmology _gvol. 146 _gno. 4 _gp. 508-12 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ajo.2008.05.036 _zAvailable from publisher's website |
| 999 |
_c18115562 _d18115562 |
||